Topiramate in migraine prevention

Expert Review of Neurotherapeutics

Volumn 3, Issue 6, 2003, Pages 761-771

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Headache; Migraine; Prevention; Topiramate

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; FLUNARIZINE; GABAPENTIN; GLUCOSE DERIVATIVE; IMIPRAMINE; METOPROLOL; MONOSACCHARIDE DEXTRO FRUCTOSE; NADOLOL; PHENOBARBITAL; PHENYTOIN; PIZOTIFEN; PRIMIDONE; PROPRANOLOL; TIMOLOL; TIMOLOL MALEATE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; ASTHENIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRADYCARDIA; CARDIOTOXICITY; CLAUDICATION; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONGENITAL DISORDER; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG STRUCTURE; DYSPEPSIA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERTHERMIA; HYPESTHESIA; IMPOTENCE; INSOMNIA; LANGUAGE DISABILITY; LETHARGY; LIVER TOXICITY; MEMBRANE BINDING; MEMBRANE CHANNEL; MEMBRANE CONDUCTANCE; MEMORY; MEMORY DISORDER; MIGRAINE; MOOD DISORDER; MYALGIA; MYOPIA; NAUSEA; NEPHROLITHIASIS; NEUROTOXICITY; NIGHTMARE; OBESITY; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PARKINSONISM; PATHOGENESIS; PHARMACODYNAMICS; PHOSPHORYLATION; PROPHYLAXIS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SWEATING; TASTE DISORDER; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0344014177     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.6.761     Document Type: Review

References (86)

1. Silberstein SD, Saper JR, Freitag F. Migraine: Diagnosis and treatment. In: Wolff's Headache and Other Head Pain. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA 121-237 (2001). Up to date review of migraine.
2. Headache Classification Committee. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1-160 (2004). New revised International Headache Society criteria.
3. Wolff HG. Headache and Other Head Pain. Oxford University Press, NY, USA (1963).
4. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. 46, 331-339 (1941).
5. Leáo AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
6. Olesen J, Friberg L, Skyhoj-Olsen T. Timing and topography of cerebral blood flow, aura and headache during migraine attacks. Ann Neurol. 28, 791-798 (1990).
7. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of RCBF in classic migraine. Ann Neurol. 9, 344-352 (1981).
8. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med 8(2), 136-142 (2002).
9. Pietrobon D, Striessnic J. Neurobiology of migraine. Nature Rev. Neurosci. 4, 386-398 (2003).
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
11. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 119, 355-361 (1996).
12. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability pain intensity attack frequency and duration. Neurology 44(4), S24-S39 (1994).
13. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 35, 387-396 (1995).
14. Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology 44(17), 4-5 (1994).
15. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology 44(Suppl. 7), 6-16 (1994).
16. Goslin RE, Gray RN, McCrory DC, Penzien D, Rains J, Hasselblad V. Behavioral and physical treatments for migraine headache. Prepared for the Agency for Healthcare Policy and Research, Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127946. February (1999).
17. Gray RN, McCrory DC, Eberlein K, Westman EC, Hasselblad V. Parenteral drug treatments for acute migraine headache. Prepared for the Agency for Healthcare Policy and Research, Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127862. (Technical Review 2.5). February (1999).
18. Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. Drug treatments for the prevention of migraine headache. Prepared for the Agency for Healthcare Policy and Research, Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127953. (Technical Review 2.3). February (1999).
19. Gray RN, McCrory DC, Eberlein K, Westman EC, Hasselblad V. Self-administered drug treatments for acute migraine headache. Prepared for the Agency for Healthcare Policy and Research, Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127854. (Technical Review 2.4). February (1999).
20. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg B. Evidence-based guidelines of the pharmacological management for prevention of migraine for the primary care provider. Neurology (1999).
21. Matchar DB, Young WB, Rosenberg JA et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Neurology (2000).
22. Silberstein SD. Preventive headache treatment. Cephalalgia 17, 67-72 (1997).
23. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 34, 497-502 (1994).
24. Silberstein SD. Methysergide. Cephalalgia 18(7), 421-435 (1998).
25. Jensen R, Brinck T, Olesen J. Sodium valproate has prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44, 241-244 (1994).
26. Klapper JA. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Quarterly 5(1), 50-53 (1995).
27. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch. Neurol. 52, 281-286 (1995).
28. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol). S. Afr. Med J. 44, 75-80 (1970).
29. Stensrud P, Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. Headache 19(6), 333-334 (1979).
30. Coulam CB, Annagers JR. New anticonvulsants reduce the efficacy of oral contraception. Epilepsia 20, 519-525 (1979).
31. Hanston PP, Horn JR. Drug interaction. Newsletter 5, 7-10 (1985).
32. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group). Headache 39(9), 633-443 (1999).
33. Silberstein SD. Divalproex sodium in headache-literature review and clinical guidelines. Headache 36(9), 547-555 (1996).
34. Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41(2), 119-128 (2001).
35. Shank RP, Gardocki JF, Vaught JL et al. Topiramate: proclinical evaluation of structurally novel anticonvulsant. Epilepsia 35(2), 450-460 (1994).
36. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 (Suppl. 1), 35-39 (2000).
37. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol. Rev. 42, 223-286 (1990).
38. MacDonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. In: Advances in Neurology. Escueta AD, Ward AA, Woodbury DM, Porter RJ (Eds). Raven Press, NY, USA, 713-736 (1986).
39. DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41 (Suppl. 1), S40-S44 (2000).
40. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Letters 231(3), 123-126 (1997).
41. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 34(Suppl. 2), 122 (1993).
42. A receptors expresses in xenopus oocytes to modulation by topiramate. Epilepsia 41 (Suppl. 1), S25-S29 (2000).
43. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl. 1), S10-S16 (2000).
44. Zhang XL, Velumian A, Jones OT, Carlen PL. Modulation of high voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41 (Suppl. 1), S52-S60 (2000).
45. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37(8), 774-780 (1996).
46. Anderson RE, Chiu P, Woodbury DM. Mechanisms of tolerance to the anticonvulsant effects of acetazolamide in mice: relation to the activity and amount of carbonic anhydrase in brain. Epilepsia 30(2), 208-216 (1989).
47. A receptors in rat CA1 pyramidal neurons. J. Neurophysiol. 77(4), 2213-2218 (1997).
48. A receptors. Science 269(5226), 977-981 (1995).
49. Krebs EG. The growth of research on protein phosphorylation. Trends Biochem Sci. 19(11), 439 (1994).
50. Roche KW O'Brien RJ, Mammen AL, Huganir RL. Characterization of multiple phosphorylation sites on the AMP receptor GIuR1 subunit. Neurone 16(6), 1179-1188 (1996).
51. Wang JH, Kelly PT. Postsynaptic injection of CA2+/CaM induces synaptic potentiation requiring CaMKII and PKC activity. Neurone 15(2), 443-452 (1995).
52. A and NMDA receptor channels by phosphorytadon. J. Receptor Signal Transduction Res. 15 (1-4), 325 (1995).
53. Shank RP, Gardocki JF, Streeter AJ, Maryanoff B. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41 (S1), S3-S9 (2000). Excellent overview of the pharmacology of topiramate.
54. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 60(Suppl. 1), A238 (2003).
55. Streeter AJ, Stahle PL, Hills JF et al. Pharmacokinetics of topiramate in the rat. Pharm. Res. 11, 372 (1994).
56. Easterling DE, Zakszewski T, Moyer MD. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia 29, 662 (1988).
57. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: a pilot study. Cephalalgia 19, 379-380 (1999).
58. Edwards KR, Glantz MJ, Shea P, Norton JA, Cross N. A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headache with and without aura. Cephalalgia 20, 316 (2000).
59. Potter DL, Hart DE, Calder CS, Storey JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 54(7 Suppl. 30), A15 (2000).
60. Silberstein SD, Bhattacharaya S, Neto W, Jacobs D. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Cephalagia (In Press) (2003).
61. Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22(8), 659-663 (2002).
62. Mathew NT, Kailasam J, Fischer A. Prophylaxis of migraine with topiramate: a retrospective analysis. Cephalalgia 21 (4), 370 (2001).
63. Brandes JL, Jacobs D, Neto W, Bhattacharaya S. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled parallel study (MIGR-002). Neurology 60 (5 Suppl. 1), A238 (2003).
64. Diener HC, Tfelt-Hansen P, Dahlof C et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial including an active comparator-propranolol. Cephalalgia 23(7), 691 (2003). First large-scale topiramate trial.
65. Jones MW. Topiramate. Epilepsia 40(Suppl. 5), S71-S80 (1999).
66. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res. 27, 29-32 (1997).
67. Sachedo RC. Topiramate. Clin. Pharm. 34, 335-346 (1998).
68. Krauss G, Crone N. Noncentral nervous system side effects of antiepileptic drugs. Neurol. Neurosurg. 1(1), 12 (2000).
69. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium Headache 42, 85 (2002).
70. Sachedo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 38, 294-300 (1997).
71. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41(Suppl. 1), S66-S71 (2000).
72. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide and uncoupling-protein mRNAs. Nutrition 16, 967-975 (2000).
73. Richard D, Ferland J, Lalonde J et al. Influence of topiramate in the regulation of energy balance. Nutrition 16, 961-966 (2000).
74. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 4(Suppl. 2), S42-S51 (2000).
75. Thomson Healthcare. Physician's Desk Reference. 57th Edition. Thomson PDR, NJ, USA (2003).
76. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59, 1011-1014 (2002).
77. Kempsford RD, Baille P, Fuseau E. Oral naratriptan tablets (2.5mg-10mg) exhibit dose-proportional pharmacokinetics. Neurology 48(3), A66 (1997).
78. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults. JAMA 288, 1723-1727 (2002).
79. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N. EngL J. Med 341, 427-434 (1999).
80. Dursun SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? Can. J. Psychiatr. 46, 287-288 (2001).
81. Loewinger LE, Young WB. Headache preventives: effect on weight. Neurology 58(7)(Suppl. 3), A286 (2002).
82. Masand PS. Weight gain associated with psychotropic drugs. Exp. Opin. Pharmacother. 1, 377-389 (2000).
83. deToledo JC, Toledo C, deCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 19, 394-396 (1997).
84. Rossner S, Taylor CL, Byington RP, Furberg CD. Long-term propranolol treatment and changes in body weight after myocardial infarction. Br. Med. J. 300, 902-903 (1990).
85. World Health Organization. World Health Report. 7-18-0002 (2001). www.who.int/whr/index.htm (Accessed October 2003)
86. National Institutes of Health. The practical guide: identification, evaluation and treatment of overweight and obesity in adults. 4-9-0003 (2003). www.nhibi.nih.gov/guidelines/obesity/ pracgde.htm (Accessed October 2003)